Filing summary
Issuer discrepancy: The request identifies ELUTIA INC., but the supplied Form 10-Q is for Aziyo Biologics, Inc. (Nasdaq: AZYO). This summary reflects the filing provided.
Business context and reporting period
Aziyo is a commercial-stage regenerative medicine company whose products serve implantable-device, cardiovascular, orthopedic/spinal repair, and soft-tissue reconstruction markets. It also processes and sells tissue products under contract manufacturing arrangements. This unaudited Form 10-Q reports the quarter and six months ended June 30, 2022; comparisons are with the corresponding 2021 periods.
Financial performance
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 | Comparable 2021 period |
|---|---|---|---|
| Net sales | $12.6 million, up 3.9% | $24.1 million, down 3.6% | $12.2 million quarterly; $25.0 million six-month |
| Gross profit / margin | $4.9 million / 38.8% | $9.2 million / 38.0% | $5.6 million / 46.2%; $11.9 million / 47.7% |
| Operating expenses | $13.1 million | $24.3 million | $10.2 million; $20.2 million |
| Loss from operations | $8.2 million | $15.1 million | $4.6 million; $8.3 million |
| Net loss | $9.4 million; $0.69 per share | $17.5 million; $1.29 per share | $2.4 million; $0.23 per share, and $7.5 million; $0.73 per share |
For the quarter, Core Product sales fell 9.3% to $9.1 million, while Non-Core sales rose 64.4% to $3.6 million. For the six months, Core Product sales fell 16.7% to $17.2 million and Non-Core sales increased 57.7% to $6.9 million. Management attributed the Core decline chiefly to Medtronic ceasing FiberCel purchases after the recall; growth in contract manufacturing, including sales to ACE Surgical Supply, drove Non-Core gains.
Gross margin fell in both periods, which management attributed primarily to a higher share of lower-margin Non-Core sales. Operating expenses increased, including sales and marketing, general and administrative, and research and development costs. R&D spending included final development and testing of CanGaroo with antibiotics. Interest expense was $1.2 million for the quarter and $2.4 million for the six months.
Cash, debt, and liquidity
- At June 30, 2022, cash and restricted cash totaled $16.5 million, versus $30.4 million at December 31, 2021. Current assets were $34.7 million and current liabilities were $34.7 million; stockholders’ equity was a deficit of $1.4 million.
- Six-month cash used in operating activities was $10.7 million, compared with $6.0 million in 2021. Investing activities used $0.3 million and financing activities used $3.0 million. Cash and restricted cash decreased $13.9 million during the six months.
- At June 30, debt consisted of $13.8 million under the term facility, $6.5 million under the revolving facility, and a $1.4 million tissue-supplier note. The balance sheet also showed a $19.2 million revenue interest obligation, including $7.8 million current. Revolver availability was approximately $1.0 million.
- On August 10, 2022, after quarter-end, the company entered into a $25 million SWK term facility: $21 million was funded at closing and another $4 million was conditional on specified metrics. The company used proceeds to repay the prior term and revolving facilities, associated fees, and the tissue-supplier note. The new facility matures in 2027, bears interest based on Term SOFR plus a stated margin, and includes revenue and liquidity covenants. The filing does not state that this refinancing eliminated liquidity concerns.
Material changes, outlook, and risks
- Year-over-year net losses increased substantially. The comparison was affected by $3.6 million of other income in the first half of 2021, including forgiveness of a $3.0 million PPP loan and a $0.55 million KeraLink settlement receipt; there was no comparable other income in 2022.
- Management stated that losses and cash outflows are expected to continue and that profitability timing is uncertain; the company may never become profitable. No specific revenue or earnings guidance was provided. Management cited historical seasonality, with sales generally higher in the fourth quarter.
- The filing states there is substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements, even after the August refinancing. Management said available cash, facility availability, and expected sales may not suffice for anticipated operating needs.
- The June 2021 voluntary recall involved one lot of FiberCel. As of the filing, 51 lawsuits and 43 additional claims were reported. The company said it could not estimate a probable loss range; any loss could materially affect its financial position and results. Insurance coverage is uncertain and may not cover all costs or damages.
- COVID-19-related disruption to medical procedures and facility operations may affect sales. Other stated risks include dependence on commercial partners and limited suppliers, competition, and the ability to fund operations. A Ligand revenue-interest agreement requires 5% of specified product sales, subject to annual minimum payments of $2.75 million; management forecast the first $5 million sales milestone payment could be due in mid-2023.
- Leadership changed during the period: C. Randal Mills became interim CEO in June and was appointed CEO in August 2022. The filing describes severance and potential bonus obligations for former CEO Ronald Lloyd.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Aziyo Biologics, Inc., not Elutia Inc.
- Review the August 2022 SWK loan agreement, its covenants, interest and payment terms, and the conditions for drawing the additional $4 million; assess liquidity after the refinancing.
- Track operating cash burn, sales trends, and gross margins, especially the mix and performance of Core versus Non-Core Products.
- Monitor FiberCel litigation, claim counts, insurance responses, and whether the company can estimate or accrue related losses.
- Verify the timing and ability to fund Ligand minimum and milestone payments, and assess potential dilution from financing or equity awards.